Sutro Biopharma, INC Form 4 insider transactions

Jane Chung, COO of Sutro Biopharma, reports the vesting of restricted stock units and associated tax withholding.

CFO of Sutro Biopharma, Edward Albini, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Jane Chung, COO of Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations related to restricted stock units.

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

William J. Newell, CEO of Sutro Biopharma, reports the vesting and tax withholding of restricted stock units (RSUs) and transactions involving common stock.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations.

Anne Elizabeth Borgman, Chief Medical Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Sutro Biopharma's President and COO, Jane Chung, reports the acquisition of 25,000 shares through vesting of restricted stock units and the withholding of 8,920 shares for tax obligations.

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Jane Chung, COO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Director Sukhi Jagpal reports the acquisition of stock options in Sutro Biopharma, Inc.

Barbara Leyman, Chief Business Development Officer at Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) on July 8, 2024.

Director Jon Marc Wigginton of Sutro Biopharma, Inc. acquired 35,000 stock options on June 6, 2024, according to a recent SEC Form 4 filing.

Director Daniel H. Petree acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Director James P. Panek acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Director Connie Matsui acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Director Joseph M. Lobacki reports acquisition of 35,000 stock options in Sutro Biopharma, Inc.

Director Heidi Hunter acquired stock options in Sutro Biopharma, Inc. on June 6, 2024.

Director John Gordon Freund acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Director Michael Dybbs reports the acquisition of stock options in Sutro Biopharma, Inc.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, exercised stock options and disposed of shares to cover tax obligations on May 1, 2024.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

William Newell, CEO of Sutro Biopharma, files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) granted on March 5, 2024.

Linda A. Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, Inc., amends a previous Form 4 filing to correct the number of restricted stock units (RSUs) granted on March 5, 2024.

Edward Albini, CFO of Sutro Biopharma, files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) granted on March 5, 2024.

Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs), as well as the disposal of shares to cover tax obligations.

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, received stock options and restricted stock units (RSUs) on March 5, 2024.

CEO William Newell reports acquisition and disposal of Sutro Biopharma stock and derivative securities, including stock options and restricted stock units (RSUs), through vesting and tax withholding.

Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, acquired stock options for 60,000 shares and 45,000 restricted stock units (RSUs) on March 5, 2024.